Form D · Biotechnology
AmpliPhi Biosciences Corp
Glen Allen, VA · CIK 0000921114
Offering snapshot reported Mar 30, 2015 · SEC filing
- Reported sold
- $13M Offering amount: $13M
- Investors reported
- 21 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 16, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 30, 2015 | Initial | $13,000,000 | No comparison | 21 | SEC filing |
| Jan 2, 2014 | Initial | $18,001,750 | No comparison | 26 | SEC filing |
| Aug 8, 2013 | Amendment | $13,320,276 | $0vs Jul 31, 2013 | 27 | SEC filing |
| Jul 31, 2013 | Amendment | $13,320,276 | $829,277vs Jul 10, 2013 | 27 | SEC filing |
| Jul 10, 2013 | Initial | $12,490,999 | No comparison | 8 | SEC filing |
| Feb 25, 2013 | Initial | $500,000 | No comparison | 1 | SEC filing |
| Nov 20, 2006 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $790K
- Finders' fees
- $0
- Form D file number
- 021-236859
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Griffin Securities, Inc. | 43229 | Griffin Securities, Inc. · CRD 43229 |
| Roth Capital Partners, LLC | 15407 | Roth Capital Partners, LLC · CRD 15407 |
Source: Form D, filed Mar 30, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| David E. Bosher | Executive |
| Jeremy Curnock Cook | Director, Executive |
| Louis Drapeau | Director |
| Anthony Gellert | Director |
| Wendy S. Johnson | Director, Executive |
| Julian P. Kirk | Director |
| Michael S. Perry | Director |
| Baxter F. Phillips, Iii | Executive |
| Anthony Smithyman | Director |
| Kelley Wendt | Executive |
| Caroline Williams | Director |
| Philip Young | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4870 Sadler Road Suite 300
Glen Allen, VA, 23060
Glen Allen, VA, 23060